Novo Nordisk's Wegovy Conundrum: A Pill That's Prescribing Uncertainty Novo Nordisk CEO Mike Doustdar has reassured investors that the company's Wegovy pill can drive profitable growth, despite lower prices weighing on sales.
However, a closer examination of the company's quarterly results and market dynamics suggests that this narrative may be more spin than substance.
The Danish company's adjusted sales rose 7% at constant exchange rates in the latest quarter, while operating profit increased 11%. But these numbers are influenced by temporary factors such as rebate adjustments.